Cargando…

Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein

Eastern equine encephalitis virus (EEEV) is a mosquito-transmitted alphavirus with a high case mortality rate in humans. EEEV is a biodefense concern because of its potential for aerosol spread and the lack of existing countermeasures. In this study, we identified a panel of 18 neutralizing murine m...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Arthur S., Austin, S. Kyle, Gardner, Christina L., Zuiani, Adam, Reed, Douglas S., Trobaugh, Derek W., Sun, Chengqun, Basore, Katherine, Williamson, Lauren E., Crowe, James E., Slifka, Mark K., Fremont, Daved H., Klimstra, William B., Diamond, Michael S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294662/
https://www.ncbi.nlm.nih.gov/pubmed/30455470
http://dx.doi.org/10.1038/s41564-018-0286-4
_version_ 1783380771267936256
author Kim, Arthur S.
Austin, S. Kyle
Gardner, Christina L.
Zuiani, Adam
Reed, Douglas S.
Trobaugh, Derek W.
Sun, Chengqun
Basore, Katherine
Williamson, Lauren E.
Crowe, James E.
Slifka, Mark K.
Fremont, Daved H.
Klimstra, William B.
Diamond, Michael S.
author_facet Kim, Arthur S.
Austin, S. Kyle
Gardner, Christina L.
Zuiani, Adam
Reed, Douglas S.
Trobaugh, Derek W.
Sun, Chengqun
Basore, Katherine
Williamson, Lauren E.
Crowe, James E.
Slifka, Mark K.
Fremont, Daved H.
Klimstra, William B.
Diamond, Michael S.
author_sort Kim, Arthur S.
collection PubMed
description Eastern equine encephalitis virus (EEEV) is a mosquito-transmitted alphavirus with a high case mortality rate in humans. EEEV is a biodefense concern because of its potential for aerosol spread and the lack of existing countermeasures. In this study, we identified a panel of 18 neutralizing murine monoclonal antibodies (mAbs) against the EEEV E2 protein, several of which had “elite” activity with 50% and 99% inhibitory concentrations (EC(50) and EC(99)) of less than 10 and 100 ng/ml, respectively. Alanine-scanning mutagenesis and neutralization escape mapping analysis revealed epitopes for these mAbs in domains A or B of the E2 glycoprotein. A majority of the neutralizing mAbs blocked at a post-attachment stage, with several inhibiting viral membrane fusion. Administration of one dose of anti-EEEV mAbs protected mice from lethal subcutaneous or aerosol challenge. These experiments define the mechanistic basis for neutralization by protective anti-EEEV mAbs and suggest a path forward for treatment and vaccine design.
format Online
Article
Text
id pubmed-6294662
institution National Center for Biotechnology Information
language English
publishDate 2018
record_format MEDLINE/PubMed
spelling pubmed-62946622019-05-19 Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein Kim, Arthur S. Austin, S. Kyle Gardner, Christina L. Zuiani, Adam Reed, Douglas S. Trobaugh, Derek W. Sun, Chengqun Basore, Katherine Williamson, Lauren E. Crowe, James E. Slifka, Mark K. Fremont, Daved H. Klimstra, William B. Diamond, Michael S. Nat Microbiol Article Eastern equine encephalitis virus (EEEV) is a mosquito-transmitted alphavirus with a high case mortality rate in humans. EEEV is a biodefense concern because of its potential for aerosol spread and the lack of existing countermeasures. In this study, we identified a panel of 18 neutralizing murine monoclonal antibodies (mAbs) against the EEEV E2 protein, several of which had “elite” activity with 50% and 99% inhibitory concentrations (EC(50) and EC(99)) of less than 10 and 100 ng/ml, respectively. Alanine-scanning mutagenesis and neutralization escape mapping analysis revealed epitopes for these mAbs in domains A or B of the E2 glycoprotein. A majority of the neutralizing mAbs blocked at a post-attachment stage, with several inhibiting viral membrane fusion. Administration of one dose of anti-EEEV mAbs protected mice from lethal subcutaneous or aerosol challenge. These experiments define the mechanistic basis for neutralization by protective anti-EEEV mAbs and suggest a path forward for treatment and vaccine design. 2018-11-19 2019-01 /pmc/articles/PMC6294662/ /pubmed/30455470 http://dx.doi.org/10.1038/s41564-018-0286-4 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Kim, Arthur S.
Austin, S. Kyle
Gardner, Christina L.
Zuiani, Adam
Reed, Douglas S.
Trobaugh, Derek W.
Sun, Chengqun
Basore, Katherine
Williamson, Lauren E.
Crowe, James E.
Slifka, Mark K.
Fremont, Daved H.
Klimstra, William B.
Diamond, Michael S.
Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein
title Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein
title_full Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein
title_fullStr Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein
title_full_unstemmed Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein
title_short Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein
title_sort protective antibodies against eastern equine encephalitis virus bind to epitopes in domains a and b of the e2 glycoprotein
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294662/
https://www.ncbi.nlm.nih.gov/pubmed/30455470
http://dx.doi.org/10.1038/s41564-018-0286-4
work_keys_str_mv AT kimarthurs protectiveantibodiesagainsteasternequineencephalitisvirusbindtoepitopesindomainsaandbofthee2glycoprotein
AT austinskyle protectiveantibodiesagainsteasternequineencephalitisvirusbindtoepitopesindomainsaandbofthee2glycoprotein
AT gardnerchristinal protectiveantibodiesagainsteasternequineencephalitisvirusbindtoepitopesindomainsaandbofthee2glycoprotein
AT zuianiadam protectiveantibodiesagainsteasternequineencephalitisvirusbindtoepitopesindomainsaandbofthee2glycoprotein
AT reeddouglass protectiveantibodiesagainsteasternequineencephalitisvirusbindtoepitopesindomainsaandbofthee2glycoprotein
AT trobaughderekw protectiveantibodiesagainsteasternequineencephalitisvirusbindtoepitopesindomainsaandbofthee2glycoprotein
AT sunchengqun protectiveantibodiesagainsteasternequineencephalitisvirusbindtoepitopesindomainsaandbofthee2glycoprotein
AT basorekatherine protectiveantibodiesagainsteasternequineencephalitisvirusbindtoepitopesindomainsaandbofthee2glycoprotein
AT williamsonlaurene protectiveantibodiesagainsteasternequineencephalitisvirusbindtoepitopesindomainsaandbofthee2glycoprotein
AT crowejamese protectiveantibodiesagainsteasternequineencephalitisvirusbindtoepitopesindomainsaandbofthee2glycoprotein
AT slifkamarkk protectiveantibodiesagainsteasternequineencephalitisvirusbindtoepitopesindomainsaandbofthee2glycoprotein
AT fremontdavedh protectiveantibodiesagainsteasternequineencephalitisvirusbindtoepitopesindomainsaandbofthee2glycoprotein
AT klimstrawilliamb protectiveantibodiesagainsteasternequineencephalitisvirusbindtoepitopesindomainsaandbofthee2glycoprotein
AT diamondmichaels protectiveantibodiesagainsteasternequineencephalitisvirusbindtoepitopesindomainsaandbofthee2glycoprotein